ID   MVD1_HUMAN              Reviewed;         400 AA.
AC   P53602; Q53Y65;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 151.
DE   RecName: Full=Diphosphomevalonate decarboxylase;
DE            EC=4.1.1.33;
DE   AltName: Full=Mevalonate (diphospho)decarboxylase;
DE            Short=MDDase;
DE   AltName: Full=Mevalonate pyrophosphate decarboxylase;
GN   Name=MVD; Synonyms=MPD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, SUBUNIT, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=8626466; DOI=10.1074/jbc.271.14.7895;
RA   Toth M.J., Huwyler L.;
RT   "Molecular cloning and expression of the cDNAs encoding human and
RT   yeast mevalonate pyrophosphate decarboxylase.";
RL   J. Biol. Chem. 271:7895-7898(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=9392419;
RA   Hinson D.D., Chambliss K.L., Toth M.J., Tanaka R.D., Gibson K.M.;
RT   "Post-translational regulation of mevalonate kinase by intermediates
RT   of the cholesterol and nonsterol isoprene biosynthetic pathways.";
RL   J. Lipid Res. 38:2216-2223(1997).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   INVOLVEMENT IN POROK7, AND VARIANTS POROK7 ARG-101; VAL-128; GLN-161;
RP   LEU-161; GLN-228; TRP-228; SER-249; SER-292; ILE-371 DEL AND ARG-376.
RX   PubMed=26202976; DOI=10.7554/eLife.06322;
RA   Zhang Z., Li C., Wu F., Ma R., Luan J., Yang F., Liu W., Wang L.,
RA   Zhang S., Liu Y., Gu J., Hua W., Fan M., Peng H., Meng X., Song N.,
RA   Bi X., Gu C., Zhang Z., Huang Q., Chen L., Xiang L., Xu J., Zheng Z.,
RA   Jiang Z.;
RT   "Genomic variations of the mevalonate pathway in porokeratosis.";
RL   Elife 4:E06322-E06322(2015).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS), MUTAGENESIS OF ASN-17, AND
RP   CHARACTERIZATION OF VARIANT POROK7 GLN-161.
RX   PubMed=18823933; DOI=10.1016/j.abb.2008.08.024;
RA   Voynova N.E., Fu Z., Battaile K.P., Herdendorf T.J., Kim J.J.,
RA   Miziorko H.M.;
RT   "Human mevalonate diphosphate decarboxylase: characterization,
RT   investigation of the mevalonate diphosphate binding site, and crystal
RT   structure.";
RL   Arch. Biochem. Biophys. 480:58-67(2008).
CC   -!- FUNCTION: Performs the first committed step in the biosynthesis of
CC       isoprenes.
CC   -!- CATALYTIC ACTIVITY: ATP + (R)-5-diphosphomevalonate = ADP +
CC       phosphate + isopentenyl diphosphate + CO(2).
CC       {ECO:0000269|PubMed:8626466}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7.4 uM for (R)-5-diphosphomevalonate
CC         {ECO:0000269|PubMed:9392419};
CC         KM=0.32 mM for ATP {ECO:0000269|PubMed:9392419};
CC   -!- PATHWAY: Steroid biosynthesis; cholesterol biosynthesis.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:8626466}.
CC   -!- TISSUE SPECIFICITY: Expressed in heart, skeletal muscle, lung,
CC       liver, brain, pancreas, kidney and placenta.
CC       {ECO:0000269|PubMed:8626466}.
CC   -!- DISEASE: Porokeratosis 7, multiple types (POROK7) [MIM:614714]: A
CC       form of porokeratosis, a disorder of faulty keratinization
CC       characterized by one or more atrophic patches surrounded by a
CC       distinctive hyperkeratotic ridgelike border called the cornoid
CC       lamella. The keratotic lesions can progress to overt cutaneous
CC       neoplasms, typically squamous cell carcinomas. Multiple clinical
CC       variants of porokeratosis are recognized, including porokeratosis
CC       of Mibelli, linear porokeratosis, disseminated superficial actinic
CC       porokeratosis, palmoplantar porokeratosis, and punctate
CC       porokeratosis. Different clinical presentations can be observed
CC       among members of the same family. Individuals expressing more than
CC       one variant have also been reported. {ECO:0000269|PubMed:18823933,
CC       ECO:0000269|PubMed:26202976}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the diphosphomevalonate decarboxylase
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U49260; AAC50440.1; -; mRNA.
DR   EMBL; BT006930; AAP35576.1; -; mRNA.
DR   EMBL; CH471184; EAW66792.1; -; Genomic_DNA.
DR   EMBL; BC000011; AAH00011.1; -; mRNA.
DR   CCDS; CCDS10968.1; -.
DR   RefSeq; NP_002452.1; NM_002461.2.
DR   UniGene; Hs.252457; -.
DR   PDB; 3D4J; X-ray; 2.40 A; A/B=1-400.
DR   PDBsum; 3D4J; -.
DR   ProteinModelPortal; P53602; -.
DR   SMR; P53602; -.
DR   BioGrid; 110682; 35.
DR   IntAct; P53602; 9.
DR   MINT; MINT-5004338; -.
DR   STRING; 9606.ENSP00000301012; -.
DR   BindingDB; P53602; -.
DR   ChEMBL; CHEMBL4340; -.
DR   GuidetoPHARMACOLOGY; 642; -.
DR   SwissLipids; SLP:000001242; -.
DR   iPTMnet; P53602; -.
DR   PhosphoSitePlus; P53602; -.
DR   BioMuta; MVD; -.
DR   DMDM; 1706681; -.
DR   EPD; P53602; -.
DR   MaxQB; P53602; -.
DR   PaxDb; P53602; -.
DR   PeptideAtlas; P53602; -.
DR   PRIDE; P53602; -.
DR   DNASU; 4597; -.
DR   Ensembl; ENST00000301012; ENSP00000301012; ENSG00000167508.
DR   GeneID; 4597; -.
DR   KEGG; hsa:4597; -.
DR   UCSC; uc002flg.2; human.
DR   CTD; 4597; -.
DR   DisGeNET; 4597; -.
DR   GeneCards; MVD; -.
DR   HGNC; HGNC:7529; MVD.
DR   HPA; HPA041404; -.
DR   HPA; HPA048250; -.
DR   MalaCards; MVD; -.
DR   MIM; 603236; gene.
DR   MIM; 614714; phenotype.
DR   neXtProt; NX_P53602; -.
DR   OpenTargets; ENSG00000167508; -.
DR   PharmGKB; PA31330; -.
DR   eggNOG; KOG2833; Eukaryota.
DR   eggNOG; COG3407; LUCA.
DR   GeneTree; ENSGT00390000015359; -.
DR   HOVERGEN; HBG051503; -.
DR   InParanoid; P53602; -.
DR   KO; K01597; -.
DR   OMA; GIECYYT; -.
DR   OrthoDB; EOG091G0EUU; -.
DR   PhylomeDB; P53602; -.
DR   TreeFam; TF105952; -.
DR   BioCyc; MetaCyc:ENSG00000167508-MONOMER; -.
DR   BRENDA; 4.1.1.33; 2681.
DR   Reactome; R-HSA-191273; Cholesterol biosynthesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-446199; Synthesis of Dolichyl-phosphate.
DR   SABIO-RK; P53602; -.
DR   UniPathway; UPA00063; -.
DR   ChiTaRS; MVD; human.
DR   EvolutionaryTrace; P53602; -.
DR   GenomeRNAi; 4597; -.
DR   PRO; PR:P53602; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000167508; -.
DR   CleanEx; HS_MVD; -.
DR   ExpressionAtlas; P53602; baseline and differential.
DR   Genevisible; P53602; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004163; F:diphosphomevalonate decarboxylase activity; IDA:UniProtKB.
DR   GO; GO:0030544; F:Hsp70 protein binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; TAS:Reactome.
DR   GO; GO:0006489; P:dolichyl diphosphate biosynthetic process; TAS:Reactome.
DR   GO; GO:0019287; P:isopentenyl diphosphate biosynthetic process, mevalonate pathway; IEA:InterPro.
DR   GO; GO:0008299; P:isoprenoid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   Gene3D; 3.30.230.10; -; 1.
DR   Gene3D; 3.30.70.890; -; 1.
DR   InterPro; IPR013750; GHMP_kinase_C_dom.
DR   InterPro; IPR006204; GHMP_kinase_N_dom.
DR   InterPro; IPR005935; Mev_decarb.
DR   InterPro; IPR029765; Mev_diP_decarb.
DR   InterPro; IPR020568; Ribosomal_S5_D2-typ_fold.
DR   InterPro; IPR014721; Ribosomal_S5_D2-typ_fold_subgr.
DR   Pfam; PF00288; GHMP_kinases_N; 1.
DR   PIRSF; PIRSF015950; Mev_P_decrbx; 1.
DR   SUPFAM; SSF54211; SSF54211; 1.
DR   SUPFAM; SSF55060; SSF55060; 1.
DR   TIGRFAMs; TIGR01240; mevDPdecarb; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cholesterol biosynthesis;
KW   Cholesterol metabolism; Complete proteome; Disease mutation;
KW   Lipid biosynthesis; Lipid metabolism; Lyase; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Steroid biosynthesis; Steroid metabolism; Sterol biosynthesis;
KW   Sterol metabolism.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895}.
FT   CHAIN         2    400       Diphosphomevalonate decarboxylase.
FT                                /FTId=PRO_0000087012.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895}.
FT   MOD_RES      96     96       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VARIANT     101    101       P -> R (in POROK7; unknown pathological
FT                                significance; dbSNP:rs200033380).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075052.
FT   VARIANT     128    128       A -> V (in POROK7; unknown pathological
FT                                significance; dbSNP:rs776358937).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075053.
FT   VARIANT     161    161       R -> L (in POROK7; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075054.
FT   VARIANT     161    161       R -> Q (in POROK7; 1000-fold diminution
FT                                in specific activity; dbSNP:rs144010349).
FT                                {ECO:0000269|PubMed:18823933,
FT                                ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075055.
FT   VARIANT     228    228       R -> Q (in POROK7; unknown pathological
FT                                significance; dbSNP:rs770939767).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075056.
FT   VARIANT     228    228       R -> W (in POROK7; unknown pathological
FT                                significance; dbSNP:rs776684503).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075057.
FT   VARIANT     249    249       F -> S (in POROK7; dbSNP:rs761991070).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075058.
FT   VARIANT     278    278       N -> H (in dbSNP:rs34519538).
FT                                /FTId=VAR_051605.
FT   VARIANT     292    292       N -> S (in POROK7; dbSNP:rs755948940).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075059.
FT   VARIANT     371    371       Missing (in POROK7; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075060.
FT   VARIANT     376    376       G -> R (in POROK7; unknown pathological
FT                                significance; dbSNP:rs546127665).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075061.
FT   MUTAGEN      17     17       N->A: 15-fold inflation in K(m) for
FT                                mevalonate diphosphate.
FT                                {ECO:0000269|PubMed:18823933}.
FT   STRAND       10     14       {ECO:0000244|PDB:3D4J}.
FT   STRAND       17     21       {ECO:0000244|PDB:3D4J}.
FT   STRAND       26     28       {ECO:0000244|PDB:3D4J}.
FT   TURN         29     32       {ECO:0000244|PDB:3D4J}.
FT   STRAND       33     36       {ECO:0000244|PDB:3D4J}.
FT   STRAND       38     43       {ECO:0000244|PDB:3D4J}.
FT   TURN         45     47       {ECO:0000244|PDB:3D4J}.
FT   STRAND       50     56       {ECO:0000244|PDB:3D4J}.
FT   STRAND       64     67       {ECO:0000244|PDB:3D4J}.
FT   HELIX        77     88       {ECO:0000244|PDB:3D4J}.
FT   STRAND      110    118       {ECO:0000244|PDB:3D4J}.
FT   TURN        120    122       {ECO:0000244|PDB:3D4J}.
FT   HELIX       126    139       {ECO:0000244|PDB:3D4J}.
FT   TURN        140    143       {ECO:0000244|PDB:3D4J}.
FT   HELIX       149    155       {ECO:0000244|PDB:3D4J}.
FT   HELIX       157    163       {ECO:0000244|PDB:3D4J}.
FT   STRAND      164    170       {ECO:0000244|PDB:3D4J}.
FT   STRAND      178    180       {ECO:0000244|PDB:3D4J}.
FT   STRAND      183    187       {ECO:0000244|PDB:3D4J}.
FT   HELIX       189    191       {ECO:0000244|PDB:3D4J}.
FT   STRAND      195    202       {ECO:0000244|PDB:3D4J}.
FT   HELIX       211    221       {ECO:0000244|PDB:3D4J}.
FT   HELIX       223    231       {ECO:0000244|PDB:3D4J}.
FT   HELIX       233    245       {ECO:0000244|PDB:3D4J}.
FT   HELIX       249    268       {ECO:0000244|PDB:3D4J}.
FT   STRAND      270    272       {ECO:0000244|PDB:3D4J}.
FT   HELIX       279    295       {ECO:0000244|PDB:3D4J}.
FT   STRAND      300    303       {ECO:0000244|PDB:3D4J}.
FT   STRAND      306    308       {ECO:0000244|PDB:3D4J}.
FT   STRAND      310    315       {ECO:0000244|PDB:3D4J}.
FT   HELIX       316    318       {ECO:0000244|PDB:3D4J}.
FT   HELIX       319    329       {ECO:0000244|PDB:3D4J}.
FT   TURN        337    339       {ECO:0000244|PDB:3D4J}.
FT   STRAND      340    343       {ECO:0000244|PDB:3D4J}.
FT   HELIX       352    358       {ECO:0000244|PDB:3D4J}.
FT   STRAND      366    375       {ECO:0000244|PDB:3D4J}.
FT   HELIX       385    387       {ECO:0000244|PDB:3D4J}.
FT   STRAND      392    394       {ECO:0000244|PDB:3D4J}.
SQ   SEQUENCE   400 AA;  43405 MW;  3FD4741BCC4B68D8 CRC64;
     MASEKPLAAV TCTAPVNIAV IKYWGKRDEE LVLPINSSLS VTLHQDQLKT TTTAVISKDF
     TEDRIWLNGR EEDVGQPRLQ ACLREIRCLA RKRRNSRDGD PLPSSLSCKV HVASVNNFPT
     AAGLASSAAG YACLAYTLAR VYGVESDLSE VARRGSGSAC RSLYGGFVEW QMGEQADGKD
     SIARQVAPES HWPELRVLIL VVSAEKKLTG STVGMRASVE TSPLLRFRAE SVVPARMAEM
     ARCIRERDFP SFAQLTMKDS NQFHATCLDT FPPISYLNAI SWRIIHLVHR FNAHHGDTKV
     AYTFDAGPNA VIFTLDDTVA EFVAAVWHGF PPGSNGDTFL KGLQVRPAPL SAELQAALAM
     EPTPGGVKYI IVTQVGPGPQ ILDDPCAHLL GPDGLPKPAA
//
